



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

**MEDICINES RECOMMENDED FOR NON-INCLUSION IN THE PHILIPPINE
NATIONAL FORMULARY (PNF)**

As of 13 June 2022, the Health Technology Assessment Council (HTAC) has finished the assessment and deliberation on **eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease.**

The HTAC hereby makes public the **preliminary recommendation for the non-inclusion of eribulin** attached in the Evidence Summary with supporting studies informing their recommendation. All comments, inputs, and/or appeals may be submitted until **28 June 2022** for consideration of the HTAC through email at hta@doh.gov.ph. Please use the prescribed form for appeals as can be accessed via this link: <https://hta.doh.gov.ph/topic-nomination/>

Should you wish to submit hard copies of your submissions, you may drop them off at the 4th floor, Philippine Blood Disease and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon Avenue, Quezon City.

Appeals not following the prescribed format advised above, and submitted beyond the deadline shall no longer be entertained.

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)
Director IV, Health Technology Assessment Division
Health Regulation Team